Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
649 participants
OBSERVATIONAL
2011-09-30
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Post Market Surveillance to Observe Safety of Prevenar13™ in Adults
NCT01834222
Study Investigating Administration of Prevenar for Post-Marketing Surveillance
NCT00195390
A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market
NCT06760208
Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.
NCT04551248
Prevenar (13v) Infant Drug Use Investigation
NCT02119104
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group1
13-valent pneumococcal vaccine
0.5mL IM (Intramuscular administration) as per recommended schedule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
13-valent pneumococcal vaccine
0.5mL IM (Intramuscular administration) as per recommended schedule
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
6 Weeks
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Choi's Pediatric Clinic
Wŏnju, Gangwon-do, South Korea
Seoul Children's Hospital
Osan, Gyeonggi-do, South Korea
Bundang Pediatric Clinic
Seongnam-si, Gyeonggi-do, South Korea
Teun Teun Pediatric clinic
Suwon, Gyeonggi-do, South Korea
Namujungwon Women's Hospital
Yangju, Gyeonggi-do, South Korea
Yonsei Pediatric Clinic
Yongin-si, Gyeonggi-do, South Korea
Busan National University Hospital
Busan, , South Korea
Jaeil Alliance Pediatrics Clinic
Daegu, , South Korea
Teun Teun Pediatric Clinic
Daegu, , South Korea
Eulji University Hospital
Daejeon, , South Korea
Korea University Ansan Hospital
Gyeonggi-do, , South Korea
Cha Bundang Medical Center, Cha University
Gyeonggi-do, , South Korea
Inha University Hospital
Incheon, , South Korea
Lee Ha Young Pediatrics
Incheon, , South Korea
Asan Medical Center
Seoul, , South Korea
Eulji Medical Center
Seoul, , South Korea
JaMo Women's Hospital
Suyeong-gu, , South Korea
Ulsan University Hospital
Ulsan, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B1851057
Identifier Type: OTHER
Identifier Source: secondary_id
6096A1-4029
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.